Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the European Medicines Agency (EMA) has accepted for
review a marketing authorization application (MAA) for
grazoprevir/elbasvir (100mg/50mg), an investigational, once-daily,
single-tablet combination therapy for the treatment of adult patients
with chronic hepatitis C (HCV) genotypes (GT) 1, 3, 4 or 6 infection.1
The EMA will initiate review of the MAA under accelerated assessment
timelines.
Language:
English
Contact:
Merck & Co., Inc.Media:Doris Li, 908-246-5701orSarra Herzog, 201-669-6570orInvestor:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more